ERBB2 and breast carcinoma: On this basis, and with the aim of improving the outcomes for patients with high-risk early HR-positive HER2-negative breast cancer, we designed the UNIRAD trial to evaluate the addition of 2 years of everolimus to conventional adjuvant ET.